Polpharma Biologics Group Announces That Its Joint Venture Bioeq Has Submitted a Biologics License Application (BLA) for Biosimilar Ranibizumab to the U.S. Food and Drug Administration (FDA)
WARSAW, Poland--(BUSINESS WIRE)-- #biologics--Polpharma Biologics Group joint venture Bioeq has submitted a BLA for biosimilar Ranibizumab.